MRB 0.3% Serum Effectiveness on 2 Early Clinical Markers of Photoinduced Cutaneous Aging: Actinic… (NCT05152407) | Clinical Trial Compass
UnknownNot Applicable
MRB 0.3% Serum Effectiveness on 2 Early Clinical Markers of Photoinduced Cutaneous Aging: Actinic Lentigo and Actinic Keratosis
35 participantsStarted 2022-01
Plain-language summary
The aim of this study is to evaluate effectiveness of a serum containing 0.3% of MRB, a cosmetic active ingredient, against actinic lentigo and actinic keratosis.
Who can participate
Age range40 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Minimum of 5 actinic lentigos and 3 actinic keratoses of grade 1 or 2 on each hemi-face of the face and/or hemi-cranium (in men with baldness)
* Phototype I to III
* Patients with free, informed, written consent to participate in the study.
* Women unable to conceive or women of childbearing potential with a negative urine pregnancy test and using contraception
Exclusion Criteria:
* Subjects with less than 5 actinic lentigos or less than 3 actinic keratoses of grade 1 or 2 on each hemiface of the face and/or skull (for men with baldness)
* Phototype IV to VI
* Immunocompromised subject
* Subjects with a history of skin carcinoma in the treated areas
* Subjects using another active treatment for actinic keratoses or lentigos (or having used one in the past 3 months)
* Subjects unable to understand the information (due to language or psychiatric reasons)
* Subjects without social insurance
* Pregnant women
* Breastfeeding women
* Women of childbearing age without contraception
* Subjects under legal protection measures
* Subjects unable to express their consent
* Subjects under legal protection
What they're measuring
1
To evaluate MRB 0.3% serum effectiveness after 6 months of treatment on 2 early clinical markers of photoinduced cutaneous aging: actinic lentigo and actinic keratosis